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Abstract
Background: The genetics involved in Ewing sarcoma susceptibility and prognosis are poorly understood. EWS/FLI and
related EWS/ETS chimeras upregulate numerous gene targets via promoter-based GGAA-microsatellite response elements.
These microsatellites are highly polymorphic in humans, and preliminary evidence suggests EWS/FLI-mediated gene
expression is highly dependent on the number of GGAA motifs within the microsatellite.
Objectives: Here we sought to examine the polymorphic spectrum of a GGAA-microsatellite within the NR0B1 promoter (a
critical EWS/FLI target) in primary Ewing sarcoma tumors, and characterize how this polymorphism influences gene
expression and clinical outcomes.
Results: A complex, bimodal pattern of EWS/FLI-mediated gene expression was observed across a wide range of GGAA
motifs, with maximal expression observed in constructs containing 20–26 GGAA motifs. Relative to white European and
African controls, the NR0B1 GGAA-microsatellite in tumor cells demonstrated a strong bias for haplotypes containing 21–25
GGAA motifs suggesting a relationship between microsatellite function and disease susceptibility. This selection bias was
not a product of microsatellite instability in tumor samples, nor was there a correlation between NR0B1 GGAA-microsatellite
polymorphisms and survival outcomes.
Conclusions: These data suggest that GGAA-microsatellite polymorphisms observed in human populations modulate EWS/
FLI-mediated gene expression and may influence disease susceptibility in Ewing sarcoma.
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Introduction
Ewing sarcoma is a prototypical chromosomal translocation-
associated malignancy, in which virtually all cases harbor a
balanced somatic translocation fusing the EWSR1 gene (EWS) to
a member of the (E- twenty six) ETS-family of transcription
factors, most commonly FLI1 (FLI) [1,2]. In fact, EWS/FLI and
related EWS/ETS fusions are considered pathognomonic for the
diagnosis of Ewing sarcoma. The EWS/FLI chimera product is a
potent oncogenic transcription factor, characterized by fusion of a
transcriptional-regulatory domain of EWS to the DNA binding
domain of FLI [2]. EWS/FLI is considered the master-regulator of
oncogenesis in Ewing sarcoma, regulating numerous critical gene
targets necessary for oncogenic transformation [3,4].
Genome-wide localizations studies utilizing ChIP-seq and
ChIP-chip strategies have identified many direct EWS/FLI
targets. A remarkable observation derived from these studies was
a previously unrecognized affinity of the EWS/FLI chimera for a
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repetitive GGAA-microsatellite element embedded within pro-
moter/enhancer regions of numerous upregulated gene targets [5–
8]. Forty to fifty percent of genomic EWS/FLI binding sites are
associated with these GGAA-microsatellites [7] and EWS/FLI-
mediated DNA binding and gene expression is dependent on these
repetitive GGAA response elements [5,8,9]. These findings
collectively demonstrate an unprecedented link between micro-
satellite DNA and transcriptional dysregulation in Ewing sarcoma.
Microsatellite DNA tracts represent ,3% of the human
genome and are commonly located in non-coding extra-genic
regions [10]. The repetitive nature and non-coding position of
these elements allows microsatellite DNA to experience a higher
baseline mutational rate than coding DNA. Consequently, these
genetic elements are highly polymorphic at both an individual and
population level [11]. Recently it has been shown that the GGAA-
microsatellites within two critical upregulated EWS/FLI-target
genes (NR0B1 and CAV1) are highly polymorphic in healthy
human subjects. Notably, significant length-dependent differences
were observed comparing the NR0B1 GGAA-microsatellite in
white European and African populations [12]. This is significant as
the incidence of Ewing sarcoma is 10-fold less in African
populations compared to white Europeans, irrespective of
geographic location, suggesting a likely genetic influence [13].
Furthermore, NR0B1 is among the most highly upregulated
EWS/FLI targets and is essential for oncogenesis in Ewing
sarcoma [6,14].
Initial studies characterizing the biochemical properties of these
GGAA-microsatellite response elements demonstrated EWS/FLI
DNA binding and subsequent transcriptional activation is highly
dependent on the number of GGAA motifs within in the
microsatellite: A minimum of 4 GGAA motifs is required for
initial DNA binding, and gene expression markedly increases in a
length-dependent manner with additional GGAA motifs [5,9,15].
Importantly, these early biochemical studies only characterized the
relationship of EWS/FLI DNA binding and gene expression over
a small and narrow range of 1–11 GGAA motifs. It remains
unclear how the substantially larger spectrum of GGAA-micro-
satellite polymorphisms, observed in human populations influences
EWS/FLI-mediated transcriptional activity. The goal of the
present study was to characterize the polymorphic spectrum of
the NR0B1 GGAA-microsatellite in Ewing sarcoma tumors,
define the biochemical properties of these GGAA length
polymorphisms and to determine whether clinical outcomes are
influenced by variations in these genetic elements.
Materials and Methods
Ethics statement
This study was approved by the University of Utah, Office for
Research Integrity and Compliance prior to commencement. All
patients enrolled in the Children’s Oncology Group (COG) study
AEW0031 (or legal guardians) provided written informed consent
prior to study enrollment, which included the use of patient
samples and tissues for molecular studies. All patient samples
analyzed in the present study were de-identified and re-identifi-
cation of samples was strictly reserved for the COG Statistics and
Data Center to perform the appropriate clinical outcomes analysis.
This study was carried out in accordance with the Declaration of
Helsinki.
Patient samples
Ewing sarcoma tissue samples were obtained from the
Biopathology Center (Columbus, OH), which serves as the
specimen bank for the Children’s Oncology Group. Patient
demographics such as age, sex and race were self-reported by
the patient (or legal guardians) at the time of study enrollment.
Patients were instructed to identify their race as Caucasian,
African American, Asian, Pacific Islander, American Indian or
other. DNA from these tissue samples was extracted from OCT
embedded tissue blocks or snap frozen tumors courtesy of Dr. Julie
Bridge (University of Nebraska Medical Center, Omaha, NE).
Approximately 20 nanograms of extracted genomic DNA also
were commercially amplified using Qiagen’s REPLI-g service
(Qiagen Genomic Services, Hilden, Germany) for whole genomic
amplification (WGA).
A second cohort of 20 Ewing sarcoma tumor samples and
matching bone marrow aspirates collected at our local institute
were also obtained. Tissues were stored in FFPE blocks and 5-
micron scrolls were cut from each block in triplicate. DNA was
extracted using the RecoverAllTm Total Nucleic Acid Isolation Kit
(Life Technologies, Carlsbad, CA).
PCR sequencing
Forward and reverse primers, flanking the NR0B1 GGAA-
microsatellite loci were designed using promoter sequences
obtained from the University of California Santa Cruz Human
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway).
All polymerase chain reaction (PCR) amplifications were per-
formed using Pfx polymerase (Invitrogen, Grand Island, NY) in
accordance with established laboratory protocols for microsatellite
DNA. Each 25 mL PCR reaction consisted of 40–80 ng of
genomic DNA, 0.3 mM of forward and reverse primers, 1U of Pfx
polymerase, 0.8 mM of each deoxyribonucleotide triphosphate,
1X Pfx buffer and 1X Pfx enhancer solution. PCR products were
subcloned into competent DH5a E. coli, with each bacterial
colony representing an individual PCR-amplification clone.
Twelve clones for each subject were selected and commercially
sequenced (Beckman Coulter Genomics, Danvers, MA).
PCA analysis
NR0B1 GGAA-microsatellite sequence data for all samples
were aligned using clustalx2. Because computational methods
perform poorly on repetitive sequence, manual refinement was
also necessary. Alignments in the repetitive regions were anchored
on eight different single nucleotide adenosine residues that
partition the contiguous GGAA repeats from the largest observed
GGAA-microsatellite. The first 29 and last 50 bases of each raw
sequence file were considered non-repetitive. For each contiguous
GGAA segment, the number of GGAA repeats was counted and
the count of the base differences between each non-repetitive
region and the consensus sequence was determined (gap
weight = 0.25). The pairwise distances between haplotypes were
calculated as the squared Euclidian distance based on the 11
variable segments. Principal components analysis was performed
using the MATLAB software package (The Mathworks, Natick,
MA).
Luciferase Experiments
The pGL3 promoter luciferase vector (Promega, Madison, WI)
was used for all experimental and control conditions. Human-
derived NR0B1 GGAA-microsatellite polymorphisms or synthetic
GGAA constructs were cloned directly upstream of the SV40
minimal promoter element. 293EBNA cells were transfected with
experimental reporter plasmid constructs or control plasmids, the
Renilla plasmid and plasmids with and without EWS/FLI cDNA.
Firefly luciferase activity was normalized to Renilla luciferase
activity to control for transfection efficiency. Each experimental
NR0B1 Microsatellite Polymorphisms in Ewing Sarcoma
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condition was performed in triplicate. Two-tailed Student’s t tests
were used for statistical comparisons.
Quantitative reverse-transcriptase polymerase chain
reaction
Total RNA from established Ewing sarcoma cell lines (A673,
COG-E-352, RDES, TC71 and SKES1) [16–19] and 293EBNA
cells was amplified and detected using SYBR green fluorescence
for quantitative analysis [20]. Normalized fold NR0B1 expression
in each of the Ewing sarcoma cell lines was calculated by
determining the fold-change of each cell line relative to 293EBNA
cells (negative control), with the data in each condition normalized
to an internal housekeeping control gene RPL21. All experiments
were performed in triplicate. Two-tailed Student’s t tests were used
for statistical comparisons.
Microarray data
Total RNA was extracted from fresh-frozen tumor specimens
using miRNAeasy columns (Qiagen). RNA was then processed
and hybridized to Affymetrix HuEx 1.0 arrays in the Genome
Core at Children’s Hospital Los Angeles according to standard
Affymetrix protocols. Data for core probeset regions were
quantile-normalized using robust multi-chip averaging in the
Partek Genomics Suite software platform (Partek, St. Louis, Mo).
NR0B1 transcript level data were derived from normalized exon
data using median summarization. Two-tailed Student’s t tests
were used for statistical comparisons.
Clinical outcomes analysis
Biological specimens were obtained from tissue submitted with
consent for banking from eligible patients enrolled on COG study
AEWS0031 [21]. The primary objective of that trial was to
compare two chemotherapy regimens with respect to risk for an
analytic event (EFS). Enrollment of 4.5 years with an additional
year of follow-up provided for the detection of a hazard ratio (HR)
of 0.64 in the failure rate with a probability of 0.80 when using a
two-sided test with size 0.05. Four instances of interim monitoring
were planned.
The primary study endpoint was event-free survival (EFS)
defined as the time from entry into the study until the occurrence
of an event (disease progression, second malignant neoplasm, or
death) or until the last contact with the patient, whichever came
first. Patients who did not experience an event by the time of last
contact were considered censored for EFS-event. The method of
Kaplan and Meier was used to estimate the probability of an event
as a function of time since enrollment. Equality of risk for EFS-
event across the various NR0B1 GGAA-microsatellite haplotypes
was assessed using the log-rank test [22]. All p-values are
calculated using the chi-squared approximation and are therefore
two-sided. EFS was assessed separately in males and females.
Patient sex was not associated with risk for events in AEWS0031
[21].
Results
Primary Ewing sarcoma tumor specimens
Ewing sarcoma tissue samples were obtained from the
Biopathology Center (Columbus, OH), which serves as the
specimen bank for the Children’s Oncology Group (COG). All
tumor samples were from patients with a pathologically confirmed
diagnosis of primary Ewing sarcoma who were enrolled in a large
multicenter COG protocol, AEWS0031 [21,23]. AEWS0031 was
opened for enrollment on May 2001 and closed in August 2005.
Data current through March 2009 (7.8 years after first enrollment)
were used in this analysis. Patients presenting with clinically
detectable metastatic disease were excluded. As part of protocol
AEWS0031, enrolled patients were prospectively randomized into
two different treatment arms: one group received the standard
chemotherapy dosing schedule (cycles every 21 days) while the
other group received interval compressed dosing (cycles every 14
days) of the same chemotherapeutic regimen, consisting of
vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophos-
phamide (1.2 g/m2) alternating with ifosfamide (9 g/m2) and
etoposide (500 mg/m2). All other study protocols were standard-
ized. Of 568 patients enrolled in AEWS0031, snap frozen (0.004–
0.06 gram) or optimal cutting temperature (OCT) compound-
embedded tissue (50–60 micron thickness) was available from 117
patients. Of this group, 5 patients were excluded: one patient was
represented in duplicate, two patients were determined to have a
final tissue diagnosis other than Ewing sarcoma, one patient
presented with metastatic disease and one patient could not be
properly identified due to a presumed clerical error. The final
analytic data set included 112 patients (Figure 1). Ninety-percent
(101/112) of patients were identified as Caucasian and only 2%
(2/112) were identified as African American. The demographic
characteristics of the included and excluded AEWS0031 patients
were comparable (Table 1).
The NR0B1 GGAA-microsatellite is highly polymorphic in
Ewing sarcoma tumors and significantly different than
white European controls
We have previously evaluated the polymorphic spectrum of
three GGAA-microsatellite containing direct EWS/FLI targets:
NR0B1, CAV1 and GSTM4 [12]. The GGAA microsatellites at
these loci are polymorphic in human populations, although
NR0B1 was the most polymorphic loci with significant differences
observed between African and Caucasian populations. Given the
markedly different incidence of Ewing sarcoma in these popula-
tions and the role of the NR0B1 protein in sustaining the
oncogenic phenotype of Ewing sarcoma, we elected to focus on
NR0B1 for this study. The NR0B1 GGAA-microsatellite,
chrX:30328826 to chrX:30329008 (http://genome.ucsc.edu/cgi-
bin/hgTracks; GRCh37/hg19) was amplified, cloned and se-
quenced in all 112 primary tumor samples. A subcloning strategy
was used to sequence all microsatellites, ensuring in heterozygous
patients that both alleles were accurately identified. A total of 143
haplotypes were identified, which was expected given 45% of the
112 patients were female. Sequence data were compared to a
previously established data set of healthy African and white
European controls [12]. It should be noted that in AEWS0031,
white, non-Hispanic patients were classified as Caucasian and in
the aforementioned data-set by Beck et al. [12], white, non-
Hispanic subjects of northern European decent are referred to as
European. For the purpose of clarity, in the present report all
white, non-Hispanic patients are reported as white Europeans.
The NR0B1 GGAA-microsatellite is located within the
promoter region, roughly 1.5 kb upstream of the transcriptional
start site. This polymorphic microsatellite ranges in length from
80–240 bp and is located within a defined haplotype block
(International HapMap project [24], CEU reference population;
Figure 2A). The GGAA-microsatellite is characterized by a series
of contiguous GGAA motifs partitioned by a single adenosine base
substitution (Figure 2B). Variability exists not only in the total
number of GGAA motifs, but also in the number of contiguous
segments and the number of GGAA motifs in each contiguous
segment. In Ewing sarcoma tumors, NR0B1 microsatellites
ranged in size from small, two-segment repeats containing 16
GGAA motifs to larger multisegment repeats containing up to 61
NR0B1 Microsatellite Polymorphisms in Ewing Sarcoma
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Figure 1. Flow diagram of COG study AEWS0031 patient samples included for GGAA-microsatellite sequencing and clinical
analysis.
doi:10.1371/journal.pone.0104378.g001
Table 1. Patient demographics of included and excluded AEWS0031 patients.
Evaluated Patients (n=112) Not Evaluated (n =456) p value*
Demographic n % n %
Age 0.04
,9 38 34% 124 27%
10–17 68 61% 271 59%
.17 6 5% 61 14%
Sex 0.8
Male 62 55% 246 56%
Female 50 45% 210 46%
Race 0.9
White European 101 90% 401 88%
African American 2 2% 12 3%
Other 3 3% 19 4%
Missing 6 5% 24 5%
Primary Tumor Site 0.4
Appendicular 44 39% 151 33%
Thoracic 16 14% 73 16%
Pelvic 20 18% 70 15%
Other Axial 9 8% 66 14%
Extraosseous 23 21% 96 21%
*Fisher’s exact test.
doi:10.1371/journal.pone.0104378.t001
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GGAA motifs. The most frequent haplotype observed in tumor
samples was an intermediate sized, 3-segment microsatellite
containing 24 GGAA motifs. A comparison of the pertinent
microsatellite sequence characteristics in tumor samples and
control white European and African populations is presented in
Table 2. The descriptive statistical analyses demonstrate that the
mean values for total number of GGAA motifs and longest
consecutive GGAA segment in the tumor dataset were similar to
that of the African data set. The white European dataset had lower
mean values for the total number of GGAA motifs compared to
both Africans and tumors. Raw sequence data of all included
subjects is listed in Table S1.
Given that 90% of the Ewing sarcoma patients analyzed in this
study were white Europeans, we sought to determine if the
spectrum of NR0B1 GGAA-microsatellite haplotypes in tumor
samples were similar to a previously established control white
European data set. To assess this a principal components analysis
(PCA) was performed combining the raw NR0B1 GGAA-
microsatellite sequences from both tumor and control white
European data sets (Figure 3A). Repetitive regions of each
sequence were manually aligned and GGAA repeat motifs were
anchored by the single nucleotide adenosine residues that partition
the contiguous GGAA repeat units observed in the largest
haplotypes. For each GGAA track, the number of GGAA repeats
units were counted. The counts of base differences between the
flanking non-repetitive regions and the consensus sequence were
also determined (gap weight = 0.25). Using this analysis, three
distinct haplotype clusters were observed in tumors, which closely
overlapped the distribution of haplotypes observed in the white
European control data set.
In contrast to the descriptive values reported in Table 2 and the
PCA analysis, which examined relationships between unique
haplotypes, when the frequency of GGAA-microsatellite haplo-
types was plotted as a function of the total number of GGAA
motifs, striking differences were observed (Figure 3B). Most
notably, a strong enrichment for haplotypes containing 21–25
GGAA motifs was observed in the tumor population: 81/143
(58%) of tumor haplotypes, compared to 46/104 (44%) and 36/
106 (34%) white European and African haplotypes, respectively,
contained 21–25 GGAA motifs (p = 0.03 and p,0.001, Chi-
square), respectively. A second enrichment was also observed for
tumor haplotypes containing 56–60 GGAA motifs: 27/143 (19%)
of tumor haplotypes, compared to 8/104 (8%) and 7/106 (7%) of
white European and African haplotypes, respectively (p = 0.03 and
p= 0.01, Chi-square). Additionally, relative to white European
controls, a depletion of haplotypes containing 16–20 GGAA motifs
was also observed in tumors. The enrichment of tumor haplotypes
containing 21–25 GGAA motifs, and the depletion of haplotypes
with 16–20 GGAA motifs, contributes to the similar descriptive
statistics shown in Table 2, despite the statistically different
distribution of these data when more sophisticated techniques
are used.
To circumvent some of the inherent bias associated with the
arbitrary binning of data, a cumulative density function was
performed for each population (Figure 3C). This figure recapitu-
lates the trends observed in Figure 3B, showing a strong
enrichment of haplotypes containing 23–26 GGAA motifs in
tumor samples, while the European density function is represented
by a larger shoulder at smaller GGAA haplotypes (16–20 GGAA
motifs) and a similar, although lower amplitude peak in the 23–26
GGAA range. The African density curve is more diffusely
populated throughout the spectrum of GGAA motifs. Using a
Kolmogorov-Smirnov test [25] to evaluate the haplotype distri-
butions based on the total number of GGAA motifs across all three
populations, the tumor data set was statistically dissimilar from
both white European (p,0.001) and African (p,0.001) popula-
tions (Figure 3C).
Using a slightly different approach, sequence data from all three
populations was stratified based on the 3 major haplotype
categories identified in the PCA analysis: 2 segment repeats with
#20 GGAA motifs, 3 segment repeats with 21–29 GGAA motifs
and a larger segmental repeats (4–8 segments) with $30 GGAA
motifs (Figure 3D). Relative to both white European and African
control populations, haplotypes containing 21–29 GGAA motifs
were statistically over-represented, while haplotypes #20 GGAA
motifs were under-represented in the tumor population (p= 0.03
Figure 2. GGAA-microsatellite organization at the NR0B1 locus. (A) Using available single nucleotide polymorphism (SNP) data from the CEU
reference population (northern and western European decent) of the International HapMap Project [24], the NR0B1 GGAA-microsatellite is identified
within a defined haplotype block. (B) For the NR0B1 locus, the GGAA-microsatellite is located approximately 1.5 kb upstream of the transcriptional
start site (TSS) and is characterized a variable number of contiguous GGAA motifs, partitioned by single adenosine base substitutions. Sequence
characteristics of interest include the total number of GGAA motifs, the total number of contiguous segments and longest consecutive GGAA
segment. Figure panel adapted from [12].
doi:10.1371/journal.pone.0104378.g002
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30614 24 1161 10
Range: 16–61 Range: 8–16
White European 24611 24 1161 11
Range: 16–60 Range: 8–16
African 32615 24 1261 11
Range: 14–72 Range: 8–21
*Mean values 6 standard deviation.
doi:10.1371/journal.pone.0104378.t002
Figure 3. NR0B1 GGAA-microsatellites are polymorphic in Ewing sarcoma tumors with an allelic distribution different than that of
white European and African controls. (A) Principal components analysis comparing unique microsatellite haplotypes in tumor samples and
white European controls demonstrate three principal sequence clusters, with a high-degree of overlap between the two populations. (B) Histogram
plots comparing the distribution frequency of NR0B1 GGAA-microsatellite haplotypes in tumors and white European and African controls. Despite the
overlapping PCA analysis, an enrichment of haplotypes containing 21–25 and 56–60 GGAA motifs was observed in tumor samples. Relative to white
Europeans, a depletion of haplotypes containing 16–20 GGAA motifs was also noted in tumors. (C) Cumulative density plots for each study
population similarly demonstrate the enrichment of haplotypes containing 21–25 and 56–60 GGAA motifs in tumors. The distribution of these
haplotypes in tumors is significantly different from both white Caucasian and African populations (KS test, p,0.001). (D) Stratifying haplotypes
according to the major sequence types identified in the PCA demonstrates that intermediate (3 segment) GGAA-microsatellites are more enriched in
tumors and larger multisegment haplotypes (.3 segments) were also more enriched compared to white Europeans, although markedly less than
Africans. Control white European and African population data from [12].
doi:10.1371/journal.pone.0104378.g003
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and p,0.0001, respectively). These data demonstrate that the
distribution of polymorphic NR0B1 GGAA-microsatellite haplo-
types in tumor samples were markedly different than white
European populations, which is compelling given the higher
incidence of Ewing sarcoma in white non-Hispanic patients of
European descent. Such observations may represent a previously
unidentified pattern of genetic susceptibility in Ewing sarcoma.
GGAA-microsatellites are genomically stable throughout
oncogenesis and after whole genome amplification
Given the non-overlapping distribution of the NR0B1 GGAA-
microsatellite haplotypes in tumor samples compared to white
European controls, we sought to determine if this difference could
be attributable to microsatellite instability during the process of
oncogenic transformation. Microsatellite instability has been
observed in various other cancers, including sarcomas, although
most commonly occurring at mono- and dinucleotide microsat-
ellite loci [26–28]. To address this question, genomic DNA was
extracted from 20 locally-archived primary or metastatic Ewing
sarcoma FFPE tissue blocks, and the NR0B1 GGAA-microsatel-
lite sequence characteristics were compared to matched germ line
DNA isolated from bone marrow aspirates. There was no evidence
of microsatellite instability in any sample (Table 3). Microsatellite
DNA stability is inversely proportional to the length of the
microsatellite tract [10] and therefore it was important to assess
the stability of the larger NR0B1 GGAA haplotypes. There was
no evidence of microsatellite instability in any of the haplotypes
containing 55–60 GGAA motifs (n = 4).
In a complementary series of experiments, we also sought to
determine if the process of whole genome amplification (WGA)
altered the composition of these GGAA-microsatellites. Given the
limited availability of tumor tissue, relatively small reserves of
DNA are available for molecular studies in Ewing sarcoma; WGA
provides an opportunity to amplify DNA from precious biological
samples. Genomic DNA from all 112 Ewing sarcoma samples was
commercially amplified using Qiagen’s Repli-g WGA service
(Qiagen Genomic Services, Hilden, Germany) and GGAA-
microsatellite characteristics were compared to unamplified
DNA. Repli-g WGA utilizes multiple displacement amplification
technology and provides a highly unbiased and complete coverage
of the genome [29]. A minimum of 10 WGA amplified tumor
samples with an NR0B1 GGAA-microsatellite sequence for each
major sequence category (,20, 20–30, 50–60 GGAA motifs) were
sequenced and compared to the unamplified, original DNA
source. GGAA-microsatellite sequences were unaltered by the
WGA process in 10/10 (100%) and 13/13 (100%) of small (,20
GGAA motifs) and medium (20–30 GGAA motifs) microsatellites,
respectively. In the largest microsatellites (50–60 GGAA motifs),
sequences were a perfect match in only 4/12 (42%) cases.
However, of the 5/7 discordant cases, the WGA sequence was
incorrect by only a single GGAA motif. In 2/12 samples, the
WGA product did not yield a sequencable amplicon (Figure 4).
These data suggest that for small and medium sized GGAA-
microsatellites, the WGA process yields highly concordant
sequences, although it introduces minor sequence perturbations
in larger repeats containing 50–60 GGAA motifs.
A narrow range of GGAA motifs facilitates maximal EWS/
FLI-mediated gene expression
Based on evidence from earlier studies, which initially
characterized GGAA-microsatellites as EWS/FLI-response ele-
ments, it appeared that after a critical threshold of 4 GGAA
motifs, DNA binding and subsequent NR0B1 gene expression
markedly increased with an increasing number of GGAA motifs.
However, more recent data has demonstrated the polymorphic
spectrum of these GGAA-microsatellites is well beyond the range
Table 3. Comparison of germline and tumor NR0B1 GGAA-microsatellites.
Patient ID Tumor Germline GGAA Tumor GGAA Alignment
EWS 17 Metastatic 25/57 25/57 Concordant
EWS 19 Primary 17/25 17/25 Concordant
EWS 22 Primary 25 25 Concordant
EWS 24 Primary 17 17 Concordant
EWS 29 Primary 24 24 Concordant
EWS 36 Primary 25 25 Concordant
EWS 41 Metastatic 25 25 Concordant
EWS 43 Metastatic 24 24 Concordant
EWS 44 Metastatic 25 25 Concordant
EWS 45 Metastatic 24 24 Concordant
EWS 46 Primary 17 17 Concordant
EWS 58 Primary 24 24 Concordant
EWS 59 Primary 24 24 Concordant
EWS 61 Primary 25/57 25/57 Concordant
EWS 62 Primary 24 24 Concordant
EWS 106 Primary 24 24 Concordant
EWS 107 Primary 58 58 Concordant
EWS 115 Primary 23 23 Concordant
EWS 116 Primary 57 57 Concordant
EWS 119 Primary 24 24 Concordant
doi:10.1371/journal.pone.0104378.t003
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tested in these earlier biochemical studies. To assess the potential
length-dependent relationship between EWS/FLI-mediated gene
expression and GGAA-microsatellite polymorphisms, various
polymorphic GGAA sequences identified in control populations
ranging from 17–72 GGAA motifs were cloned into a luciferase
reporter vector directly upstream of the SV40 minimal promoter
element. 293 EBNA cells were co-transfected with the various
experimental GGAA plasmids and a vector containing EWS/FLI
or an empty vector control. All experiments were performed in
triplicate and the luciferase data presented is a composite of two
independent experiments.
In human-derived sequences (Figure 5A), a bimodal relation-
ship of EWS/FLI-mediated gene expression across the spectrum
of GGAA constructs investigated was observed. Gene expression
was maximal in microsatellites containing 20–25 GGAA motifs,
and values precipitously dropped in constructs ranging from 29–40
GGAA motifs followed by a second lesser peak in constructs
ranging from 50–60 GGAA motifs. Relative to the 24 GGAA
construct, the reduction in expression was maximal in constructs
containing 17, 29 and 72 GGAA motifs (3-fold, 4.5-fold and 4.5-
fold; p,0.0001), respectively. Expression levels using the 58
GGAA construct were 1.5-fold less than the 24 GGAA construct
(p,0.001).
The human-derived sequences contained varying combinations
of single-base insertions and contiguous GGAA sequences, thus
complicating the interpretation of these data (see Figure 2B). To
focus the evaluation on the overall length of the GGAA-
microsatellite, synthetic GGAA-microsatellites constructs were
synthesized, ranging from 10–70 contiguous GGAA motifs and
cloned into the same luciferase vector in an identical fashion.
Similar differences were observed in the assays using the synthetic
constructs (Figure 5B). Additionally, average gene expression
levels in the assays using the contiguous synthetic constructs were
markedly elevated compared to the segmental constructs cloned
from human DNA (4586330 vs. 107662, respectively, p = 0.02).
These trends suggest contiguous GGAA-microsatellites afford
more optimal gene expression than partitioned repeats. Exempli-
fying this, gene expression in the smallest synthetic construct (10
GGAA) was 2.5-fold greater than the maximal expression
observed from the partitioned 24 GGAA construct. Interestingly,
the third segment of the 24 GGAA construct contains 10
contiguous GGAA motifs.
To assess the influence of these polymorphic GGAA-microsat-
ellite response elements in a more native cellular context, NR0B1
mRNA levels were quantified from various patient-derived Ewing
sarcoma cell lines confirmed to be polymorphic at the NR0B1
GGAA locus. Given the position of NR0B1 on the X chromo-
some, to circumvent any issues associated with heterozygosity and
potential X-linked inactivation, only cell lines either homozygous
or hemizygous for a polymorphic NR0B1 GGAA-microsatellite
locus were included. Unfortunately none of the investigated cell
lines were hemizygous or homozygous for a larger 50–60 GGAA
motif allele; two cell lines (EWS502 and TC32) were heterozygous
(20/58 GGAA and 24/58 GGAA, respectively), but a clear
Figure 4. GGAA-microsatellites sequence characteristics after whole genome amplification (WGA). Microsatellites were sequences after
WGA and compared to unamplified DNA.
doi:10.1371/journal.pone.0104378.g004
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pattern of allelic activation (or inactivation) could not be
established for these cell lines. Figure 5C illustrates quantitative
RT-PCR normalized expression levels of NR0B1 mRNA
transcripts relative to the number of GGAA motifs measured.
Similar to the luciferase experiments, maximal gene expression
was observed in cell lines ranging from 24–26 GGAA motifs.
Negligible NR0B1 levels were observed in the RDES cell line,
which is hemizygous for a 17 GGAA-microsatellite. These results
using a native cellular context strongly support the trends observed
in both patient-derived and synthetic luciferase experiments of
maximal gene expression in constructs containing 20–25x GGAA
motifs.
When comparing the gene expression profiles (Figure 5) to the
allelic distributions of the NR0B1 GGAA-microsatellite sequenced
from tumor samples (Figure 3), striking similarities are observed.
Notably, the bimodal pattern of maximal gene expression and the
amplitude of these peaks in constructs ranging from 20–25x and
56–60x GGAA motifs parallels the frequency and distribution of
NR0B1 GGAA-microsatellite in tumors.
To investigate if GGAA-microsatellite polymorphisms influ-
enced NR0B1 gene expression in Ewing sarcoma tumors, we
quantified normalized NR0B1 expression using microarray data
from 31 Ewing sarcoma samples from which both PCR
sequencing data and RNA were available. Ten of the 31 samples
were heterozygous at the NR0B1 GGAA-microsatellite locus,
leaving 21 hemi- or homozygous tumors for analysis (Figure 5D).
Consistent with the cell line data in Figure 5C, we observed lower
normalized NR0B1 expression levels in tumors containing only
17–18 GGAA motifs in their NR0B1 microsatellite. This was a
statistically-significant diminished level as compared to tumors
containing 23–26 GGAA motifs (p = 0.04). Thus, the human
tumor data is consistent with the cell line and in vitro luciferase
studies.
Polymorphisms of the NR0B1 GGAA-microsatellite are not
predictive of event free survival
Given the documented influence of GGAA length polymor-
phism on gene expression and mRNA levels, we next sought to
Figure 5. EWS/FLI-mediated gene expression is highly variable across various GGAA-microsatellite length polymorphisms. (A)
Polymorphic NR0B1 GGAA-microsatellites from white European and African subjects were cloned into luciferase reporter vectors and co-transfected
with EWS/FLI into 293 EBNA cells. A bimodal pattern of gene expression was observed, with greatest expression in constructs with 24 GGAA motifs
and a lesser peak in constructs with 58 GGAA motifs. (B) A similar bimodal trend was observed using synthetic GGAA constructs identically cloned
into the same luciferase reporter construct. (C) In patient derived Ewing sarcoma cell lines, RT-PCR quantified NR0B1 mRNA expression was also
maximal in cell lines containing an NR0B1 microsatellite containing 24–26 GGAA motifs. (D) In primary Ewing sarcoma tumors, normalized NR0B1
transcript levels were lowest in tumors with NR0B1 GGAA-microsatellites containing 17–18 GGAA motifs, which was significant less than tumors with
microsatellites containing 23–26 GGAA motifs (p = 0.04).
doi:10.1371/journal.pone.0104378.g005
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determine if these polymorphisms influence tumor biology and
clinical outcomes in patients with Ewing sarcoma. NR0B1 is one
the most highly upregulated, direct EWS/FLI targets, and
expression of this gene is essential for transformation in Ewing
sarcoma cell lines [6,30]. Clinical outcome data for at least 5 years
(in surviving patients) [21] was available in all 112 samples used in
the sequencing analysis. Of the 112 patients included in the
analysis from AEWS0031, 69/112 were treated with the standard
chemotherapy regimen as compared to 43/112 treated with
compressed chemotherapy (Figure 1). It should be noted that the
5-year EFS was slightly improved in patients receiving compressed
therapy (73% vs. 65%, p= 0.048 [21]). The aggregate outcome of
patients who were considered in this analysis was similar to
patients who were eligible for AEWS0031 but who were not
included in the analysis (p = 0.21).
Given the biochemical data favoring optimal gene expression
over a narrow range of GGAA motifs and the distribution of these
haplotypes in Ewing sarcoma tumors, Kaplan-Meier survival
analyses were performed stratifying patients based on the presence
or absence of NR0B1 alleles containing 22–27 GGAA motifs
(Figure 6). The presence of one or more NR0B1 alleles containing
22–27 GGAA motifs did not influence EFS compared to patients
without these alleles (Figure 6A and 6B). Given that females
represented 45% of our cohort, numerous patients heterozygous
for different length alleles were identified. Whether one or both of
these alleles is active in tumor cells remains unclear; therefore, EFS
was assessed separately in males and females (Figure 6C and 6D).
In male and female patients, EFS was also not influenced by allele
type. Furthermore, stratifying the patients based on assignment to
standard vs. compressed chemotherapy arms also did not influence
EFS survival based on allele type (Figure 6E and 6F). These results
clearly demonstrate that despite biochemical data showing a
strong relationship between GGAA-microsatellite length and gene
expression levels, polymorphisms of the NR0B1 GGAA-micro-
satellite do not influence clinically relevant outcomes.
Discussion
Transcriptional dysregulation via microsatellite DNA in Ewing
sarcoma represents a fascinating and novel property of the EWS/
FLI chimera. Microsatellite DNA is not subject to the same
evolutionary pressures as coding DNA, rendering these sequences
highly polymorphic across individuals and populations [11,12,31].
Furthermore, given that 40–50% of genomic EWS/FLI occupan-
cy occurs at GGAA-microsatellites [7], these EWS/FLI-responsive
elements provide a unique opportunity to examine Ewing sarcoma
susceptibility and pathogenesis from an alternative genetic basis.
In particular, our research group is interested in whether
polymorphisms at transcriptionally important GGAA-microsatel-
lites are biologically relevant in this context. In the present study,
we have demonstrated that the NR0B1 GGAA-microsatellite in
primary Ewing sarcoma tumors is highly polymorphic, with an
allelic distribution dissimilar from white European controls. Here
we report the first series of biochemical experiments detailing the
effect of GGAA-microsatellite polymorphisms on EWS/FLI-
mediated transcriptional regulation demonstrating that the distri-
bution of these NR0B1 haplotypes in tumors is strongly biased
towards a narrow range of microsatellite alleles that facilitate
maximal EWS/FLI-mediated gene expression.
Traditionally viewed as ‘‘junk’’ DNA, microsatellite DNA is
becoming increasingly recognized as an important cis-regulating
genetic element [32,33]. The discovery of GGAA-microsatellites
as a direct EWS/FLI-mediated transcriptional response element in
Ewing sarcoma identified a novel function of microsatellite DNA
in human cancer development and a previously unrecognized
ETS factor binding site [34]. We have demonstrated that across a
large numeric range of GGAA motifs, EWS/FLI-mediated gene
expression is highly variable. However, contrary to our prelimi-
nary understanding of these EWS/FLI-responsive elements, we
did not observe a simple linear relationship of increasing gene
expression as a function of an increasing number of GGAA motifs
[5]. Instead, a bimodal relationship was observed. A mechanistic
explanation for this bimodal relationship was not assessed in the
present study, although similar findings have been observed in
other model systems. For instance, in Neisseria meningitides,
expression of a virulence factor, NadA is regulated by a
polymorphic, promoter-based tetranucleotide microsatellite ele-
ment with a similar pattern of transcript periodicity to that
observed in our study [35,36]. The variations in NadA transcript
levels were attributed to altered binding abilities of transcriptional
cofactors across the various microsatellite polymorphisms [36].
The EWS/FLI chimera requires a minimum of 4 contiguous
GGAA motifs (16 bp) to effectively bind microsatellite DNA.
Furthermore, EWS/FLI occupies these microsatellites in a ratio of
2 protein molecules for every DNA molecule in synthetic
microsatellite constructs comprised of 4, 5, 6 and 7 contiguous
GGAA motifs [9]. A potential explanation for the bimodal
biochemical expression patterns observed in this study is that the
stoichiometric occupancy of EWS/FLI and associated co-factors is
most optimal across microsatellites containing 21–25 or 55–60
GGAA motifs. Another possibility is that certain GGAA-micro-
satellite polymorphisms are more (or less) likely to form inhibitory
secondary DNA structures. Guanine-rich DNA sequences can
predispose to the formation of non-B-form DNA structures and G-
quadruplexes [32,37], which may influence EWS/FLI and
associated co-factor occupancy. Certainly, the results of the
luciferase, cell line, and primary human tumor data detailed in
the present study are compelling and warrant further investiga-
tions into the biochemical effects of GGAA content on EWS/FLI-
mediated DNA binding in a native cellular and chromatin context.
The incidence of Ewing sarcoma in African populations is 10-
fold less than that of white Europeans [13], but as of yet there is no
concrete explanation for this difference [38–40]. The GGAA-
microsatellite of two critical upregulated EWS/FLI-targets in
Ewing sarcoma (NR0B1 and CAV1) have been shown to be highly
polymorphic in African and white European populations, with a
predisposition for significantly larger GGAA-microsatellites in
Africans, especially at the NR0B1 locus [12]. This finding
prompted further inquiry into the makeup of these elements in
Ewing sarcoma tumor samples. Indeed, our results demonstrate
that these GGAA elements are highly polymorphic in tumors,
although the distribution of these haplotypes within primary
tumors demonstrated compelling differences compared to both
African and white European controls. The dissimilar distribution
of tumor and white European control haplotypes is an important
observation, given that 90% of the AWES0031 cohort was
identified as white European. Our preliminary hypothesis was that
the NR0B1 GGAA-microsatellite sequence data set from white
European controls would be very similar to the patient-derived
tumor samples.
Compared to white European controls, a strong enrichment for
NR0B1 microsatellite haplotypes containing either 21–25 or 56–
50 GGAA motifs and a bias against smaller alleles containing 17–
20 GGAA motifs was observed in patient samples. Given the
stability of these GGAA sequences as determined by the
comparison of tumor and germline DNA sequences, the predilec-
tion for those two allele ranges does not appear to be a product of
sequence evolution within tumor cells during the process of
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oncogenesis. Given that NR0B1 is among the most upregulated
direct EWS/FLI targets, and is essential for maintenance of
oncogenic transformation [5,6,14], two alternative hypotheses
were proposed: the predilection for the selection bias of specific
NR0B1 GGAA-microsatellite haplotypes in tumors is a conse-
quence of either superior oncogenic potential in tumors harboring
21–25 or 56–50 GGAA motifs at the NR0B1 locus or conversely,
these principal GGAA-microsatellite haplotypes observed in
tumors are important for Ewing sarcoma susceptibility and
transformation in progenitor cells harboring the EWS/FLI
translocation. The luciferase assays and qRT-PCR data from
human-derived cell lines clearly show that the most common
GGAA-microsatellite allele observed in tumors also facilitates
maximal EWS/FLI-mediated gene expression. The results from
these experiments are further supported by patterns of NR0B1
gene expression observed in tumor microarray data, wherein
tumors harboring small GGAA microsatellites (,20 GGAA
repeats, Figure 5D) are those that have the lowest levels of
NR0B1 gene expression. Although interpretation of tumor
microarray experiments is limited by the small number of samples
included, the limited number of samples available with smaller
numbers of GGAA repeats further supports the hypothesis that
Ewing sarcoma tumor development is restricted by lower levels of
NR0B1 expression in the setting of these small GGAA-microsat-
ellites. Thus, these results provide additional supportive data in a
more biologically relevant context. Likewise, the clinical analysis of
AEWS0031 patients demonstrates that EFS is not influenced by
Figure 6. NR0B1 GGAA-microsatellite polymorphisms do not influence event free survival (EFS) in Ewing sarcoma patients. (A) EFS
was compared in 112 patients from AEWS0031 based on the presence of absence of at least one NR0B1 GGAA-microsatellite allele containing 22–27
GGAA motifs. This allele type was chosen based on the pattern of alleles present in tumor samples and the maximal EWS/FLI-mediated gene
expression supported by alleles of this length category. (B) EFS was similarly assessed based on the presence of one or both alleles containing 22–27
GGAA motifs. Additional subgroup analyses were also performed in males (C) and females (D) and in patients receiving standard (E) or compressed
(F) therapy.
doi:10.1371/journal.pone.0104378.g006
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these NR0B1 GGAA polymorphisms, which we believe also
supports the latter hypothesis.
Assessing the clinical impact of these NR0B1 GGAA polymor-
phisms was an important outcome measure in this study and
consequently various statistical approaches were employed to
sufficiently address this association. However, when subgroup
analyses were performed to address potential confounding
influences such as patient sex, zygosity, and chemotherapy our
results clearly demonstrate that disease behavior in Ewing sarcoma
is not influenced by GGAA-microsatellite polymorphisms at the
NR0B1 locus.
Integrating the results of this study we propose that in Ewing
sarcoma, GGAA-microsatellite polymorphisms play an important
role in disease susceptibility. It is generally accepted that the
EWS/FLI translocation event is the driver oncogenic mutation in
Ewing sarcoma. We suggest that in precursor cells exposed to the
EWS/FLI chimera, cells with a more ‘permissive’ genetic
constitution of GGAA-microsatellite polymorphisms are more
likely to transform when exposed to the EWS/FLI chimera than
cells with a non-permissive GGAA genotype (Figure 7). Further
supporting this model is that Ewing sarcoma is believed by many
experts to be exclusively a human condition; spontaneous cases of
Ewing sarcoma have not been observed in any other animal
species (except for a single case report in a camel [41]), and
inducible Ewing sarcoma models in murine progenitor cell and
transgenic mice do not recapitulate the molecular hallmarks of
disease [42–45]. Interestingly, the mouse orthologs of NR0B1,
CAV1, GSTM4, and FCGRT (4 microsatellite-containing upre-
gulated EWS/FLI targets in humans) do not possess a GGAA-
microsatellite in their respective promoter/enhancer regions.
Additionally, ectopic EWS/FLI expression in murine-derived
NIH3T3 cells does not upregulate Nr0b1, further supporting
observation that GGAA-microsatellites are necessary for regula-
tion of Nr0b1 in Ewing sarcoma [46]. Additional sequencing
efforts are underway to better characterize a more comprehensive
cohort of EWS/FLI-enriched GGAA-microsatellites in African,
white Europeans and Ewing sarcoma patients.
In a recent genome-wide association study three candidate
Ewing sarcoma susceptibility loci were identified using a compre-
hensive single nucleotide polymorphism (SNP) analysis [39]. The
authors demonstrated a greater frequency of these susceptibility
loci in white Europeans as compared to Africans. However, the
oncogenic contribution of these identified susceptibility loci in the
pathogenesis of Ewing sarcoma has yet to be clarified. Further-
more, it does not appear that the observed differences in the
frequency of these susceptibility loci will fully account for the 10-
fold increase in Ewing sarcoma in white Europeans compared to
Africans. EWS/FLI-responsive GGAA-microsatellites provide a
complementary genetic approach to understand these discrepant
patterns of disease incidence. These GGAA-microsatellites are
highly polymorphic and are also direct genetic targets of the
EWS/FLI chimera. Additionally, compared with white European
and Asian populations, African populations have are known to
have increased genetic diversity for many microsatellite loci [47].
Based on our biochemical data, a greater diversity of GGAA
motifs at important microsatellite loci may actually negatively
impact EWS/FLI-mediated gene expression, which appears
optimal over a narrow range of GGAA motifs. Additional work
will be needed to discern the relative contributions of microsatellite
polymorphisms and SNPs in the susceptibility to Ewing sarcoma
development.
An additional important finding gleaned from this study is that
GGAA-microsatellites are genetically stable during the process of
oncogenic transformation. Consequently, tumor tissues are not
required to obtain DNA for GGAA-microsatellite genotyping in
individuals with Ewing sarcoma. Given the current practice of
CT-guided core biopsies and neoadjuvant chemotherapy, Ewing
sarcoma tissue is infrequently available for genetic studies.
Germline sources of DNA such as blood, bone marrow aspirates,
saliva and buccal swabs are more readily available and based on
Figure 7. Model of GGAA-microsatellite polymorphism contributions to Ewing sarcoma susceptibility in African and white
European populations.
doi:10.1371/journal.pone.0104378.g007
NR0B1 Microsatellite Polymorphisms in Ewing Sarcoma
PLOS ONE | www.plosone.org 12 August 2014 | Volume 9 | Issue 8 | e104378
the results presented here, can be used in future GGAA-
microsatellite genotyping experiments. Additionally, our data also
demonstrates that commercial WGA of tumor DNA does not
erroneously expand or contract small or medium sized GGAA-
microsatellites. Even in extremely large microsatellites (50–60
GGAA motifs) discordance was minimal (1 GGAA motif).
Importantly, together these findings provide valuable insight into
the stability of GGAA-microsatellites in Ewing sarcoma, providing
an opportunity for prospective genotyping studies to progress
beyond the barriers of limited tissue supplies.
In conclusion, this report is the first detailed examination of
EWS/FLI-responsive GGAA-microsatellite polymorphisms in
Ewing sarcoma. At the NR0B1 locus, we have demonstrated that
in primary Ewing sarcoma tumor samples, there is strong
overrepresentation of a narrow range of GGAA haplotypes,
which was discordant from healthy white European controls. We
further demonstrated that maximal EWS/FLI-mediated gene
expression is also highly dependent on a comparably narrow range
of GGAA motifs. At the NR0B1 locus, these polymorphisms do
not influence clinical outcomes, favoring a model in which these
GGAA polymorphisms may contribute to the elusive permissive
cellular and genetic environment necessary for EWS/FLI-medi-
ated transformation.
Supporting Information
Table S1 Complete sequence data of NR0B1 GGAA-microsat-
ellites form all samples. In the ‘‘COG Data’’ tab all data from
Children’s Oncology Group primary tumor samples are included.
The data fields indicate the zygosity, the number of GGAA repeats
for each allele, the segment characteristics of each allele, and the
raw sequence of each allele. In the ‘‘African Data’’ and ‘‘European
Data’’ tabs, all data from the African and European subjects,
respectively, are included. The data from these latter tabs were
previously described in reference [12].
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